Abstract 5475: Development of high-throughput 3D bioprinted pediatric models for precision medicine
Authors: Valentina Poltavets, MoonSun Jung, Joanna Skhinas, Kathleen Kimpton, Alvin Kamili, Gabe Tax, Jie Mao, Louise Cui, Marie Wong, Mark J. Cowley, Loretta Lau, Emmy ME Dolman, John J. Gooding, Maria Kavallaris
Journal: Cancer Research (2024)

Abstract Childhood cancer patients with high-risk disease have poor prognosis. Therapies given to treat these patients are often highly toxic and determined empirically, exposing children to damaging and ineffective therapies. Precision medicine is a promising strategy for these patients. However, tumor biopsies often lack sufficient sample for phenotypic drug screening, requiring cell expansion via primary cell culture or development of patient-derived xenograft models - a slow process with variable success rates. There is an unmet need for sensitive, predictive, and timely drug testing models. Dynamic interactions between cells and the extracellular matrix (ECM) impact cellular signaling and response to cancer therapy. The development of patient-derived tumor models that are reflective of the patient sample and achieved in a clinically relevant timeframe will be game changing. In-silico analysis of 265 ECM gene expression from a high-risk neuroblastoma and sarcoma patient cohort (n=145) identified collagens and fibronectin to be the most abundantly expressed ECM genes in the tumor samples. To reflect this environment, we developed tuneable tissue ECM-like bioinks where cells are embedded within the bioink that mimics growth constraints within a tumor [1]. Specifically, we functionalized the bioinks with peptides of collagen I, fibronectin, and laminin to mimic the ECM environment and combined this with HTP 3D bioprinting technology to create patient-derived tumoroids. In this proof-of-concept study, we identified conditions that enable the growth and expansion of the neuroblastoma and sarcoma cells in a 3D ECM-like environment. The tumor samples proliferate in the bioinks and HTP drug screening was used to determine drug sensitivity. Importantly, the bioprinted cells reflect the genetic and phenotypic characteristics of the original patient tumors and retained their tumorigenic capacity in vivo. Collectively, we have successfully generated preclinical models that reflect patient tumors and are directly compatible with preclinical drug testing. Importantly, our 3D bioprinting platform has the potential to advance cancer precision medicine in a clinically relevant timeframe. These findings have broader applications for a range of cancer types for preclinical testing, drug discovery and cancer biology.1. Utama, RH, et al. Macromolecular Bioscience, 2021. 21(9):e2100125 Citation Format: Valentina Poltavets, MoonSun Jung, Joanna Skhinas, Kathleen Kimpton, Alvin Kamili, Gabe Tax, Jie Mao, Louise Cui, Marie Wong, Mark J. Cowley, Loretta Lau, Emmy ME Dolman, John J. Gooding, Maria Kavallaris. Development of high-throughput 3D bioprinted pediatric models for precision medicine [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 5475.